S100A12 and AGER

Number of citations of the paper that reports this interaction (PubMedID 10399917)
481

Data Source:
HPRD (in vitro, in vivo)

		S100A12	AGER
Description		S100 calcium binding protein A12	advanced glycosylation end-product specific receptor
Image
GO Annotations	Cellular Component	Extracellular Region Nucleus Cytoplasm Cytosol Cytoskeleton Plasma Membrane Secretory Granule Lumen	Fibrillar Center Extracellular Region Cell Plasma Membrane Integral Component Of Plasma Membrane Cell Surface Apical Plasma Membrane Cell Junction Postsynapse
	Molecular Function	Copper Ion Binding Calcium Ion Binding Protein Binding Zinc Ion Binding RAGE Receptor Binding	Amyloid-beta Binding Transmembrane Signaling Receptor Activity Scavenger Receptor Activity Protein Binding Signaling Receptor Activity Identical Protein Binding S100 Protein Binding Protein-containing Complex Binding Advanced Glycation End-product Receptor Activity
	Biological Process	Monocyte Chemotaxis Xenobiotic Metabolic Process Inflammatory Response Neutrophil Chemotaxis Killing Of Cells Of Other Organism Defense Response To Bacterium Positive Regulation Of I-kappaB Kinase/NF-kappaB Signaling Neutrophil Degranulation Positive Regulation Of MAP Kinase Activity Innate Immune Response Mast Cell Activation Cytokine Secretion Positive Regulation Of Inflammatory Response Defense Response To Fungus Positive Regulation Of NF-kappaB Transcription Factor Activity Antimicrobial Humoral Immune Response Mediated By Antimicrobial Peptide	Response To Hypoxia Microglial Cell Activation Regulation Of T Cell Mediated Cytotoxicity Positive Regulation Of Protein Phosphorylation Endocytosis Inflammatory Response Cell Surface Receptor Signaling Pathway Learning Or Memory Response To Wounding Glucose Mediated Signaling Pathway Neuron Projection Development Negative Regulation Of Interleukin-10 Production Positive Regulation Of Interleukin-12 Production Positive Regulation Of Heterotypic Cell-cell Adhesion Positive Regulation Of Activated T Cell Proliferation Positive Regulation Of Tumor Necrosis Factor Biosynthetic Process Positive Regulation Of JUN Kinase Activity Transcytosis Positive Regulation Of Chemokine Biosynthetic Process Innate Immune Response Positive Regulation Of Interleukin-6 Biosynthetic Process Positive Regulation Of JNK Cascade Astrocyte Activation Regulation Of Synaptic Plasticity Positive Regulation Of Interleukin-1 Beta Biosynthetic Process Induction Of Positive Chemotaxis Positive Regulation Of NF-kappaB Transcription Factor Activity Regulation Of DNA Binding Positive Regulation Of ERK1 And ERK2 Cascade Positive Regulation Of Monocyte Chemotactic Protein-1 Production Protein Localization To Membrane Modulation Of Age-related Behavioral Decline Regulation Of Spontaneous Synaptic Transmission Regulation Of Long-term Synaptic Potentiation Negative Regulation Of Long-term Synaptic Potentiation Negative Regulation Of Long-term Synaptic Depression Regulation Of P38MAPK Cascade Positive Regulation Of P38MAPK Cascade Regulation Of NIK/NF-kappaB Signaling Positive Regulation Of NIK/NF-kappaB Signaling Positive Regulation Of Aspartic-type Endopeptidase Activity Involved In Amyloid Precursor Protein Catabolic Process Negative Regulation Of Blood Circulation Positive Regulation Of Endothelin Secretion Negative Regulation Of Connective Tissue Replacement Involved In Inflammatory Response Wound Healing Response To Amyloid-beta Cellular Response To Amyloid-beta Positive Regulation Of Monocyte Extravasation Regulation Of CD4-positive, Alpha-beta T Cell Activation Positive Regulation Of Dendritic Cell Differentiation
Pathways		TAK1 activates NFkB by phosphorylation and activation of IKKs complex Neutrophil degranulation Advanced glycosylation endproduct receptor signaling Advanced glycosylation endproduct receptor signaling TRAF6 mediated NF-kB activation	TAK1 activates NFkB by phosphorylation and activation of IKKs complex Advanced glycosylation endproduct receptor signaling Advanced glycosylation endproduct receptor signaling TRAF6 mediated NF-kB activation
Drugs		Olopatadine Amlexanox
Diseases
GWAS		Asthma ( 31619474) Blood protein levels ( 30072576) Matrix metalloproteinase-8 levels ( 29212897)	Advanced glycation end-product levels ( 26083729) Asthma ( 31619474) Autism spectrum disorder or schizophrenia ( 28540026) Blood protein levels ( 29875488) Blood protein levels in cardiovascular risk ( 28369058) Chronic obstructive pulmonary disease ( 28166215 30804561) Emphysema imaging phenotypes ( 26030696) FEV1 ( 30804560) Inflammatory bowel disease ( 28067908) Lung function (FEV1/FVC) ( 28166213 30804560) Lung function (FVC) ( 30804560) Peak expiratory flow ( 30804560) Percentage gas trapping ( 26030696) Prostate cancer ( 23535732) Pulmonary function ( 20010834 20010835) Pulmonary function (smoking interaction) ( 23284291) Response to Pazopanib in cancer (hepatotoxicity) ( 26546620) Sarcoidosis (non-Lofgren's syndrome without extrapulmonary manifestations) ( 26651848) Ulcerative colitis ( 28067908)
Interacting Genes		3 interacting genes: AGER CACYBP RBX1	8 interacting genes: APP CREB3 HMGB1 S100A1 S100A12 S100B S100P TTR
Entrez ID		6283	177
HPRD ID		04383	02568
Ensembl ID		ENSG00000163221	ENSG00000204305
Uniprot IDs		P80511	A0A1U9X785 B4DNX3 Q15109
PDB IDs		1E8A 1GQM 1ODB 2M9G 2WC8 2WCB 2WCE 2WCF	1PWI 2BJP 2E5E 2ENS 2L7U 2LE9 2LMB 2M1K 2MJW 2MOV 3CJJ 3O3U 4LP4 4LP5 4OF5 4OFV 4OI7 4OI8 4P2Y 4XYN 4YBH 5D7F
Enriched GO Terms of Interacting Partners?
Tagcloud ?
Tagcloud (Difference) ?
Tagcloud (Intersection) ?